1st Quarter of FY 2026
IR Materials

NIPRO CORPORATION
Board Director, CFO,
Senior Managing Officer
Takehito Yogo
August 10, 2026

NIPRO

Disclaimer

NIPRO

Forecasts and other forward-looking statements contained in this document are based on information currently available to the Company and on certain assumptions that the Company considers reasonable. Actual results may differ materially from those expressed or implied in these statements due to various factors and uncertainties that may arise in the future.

Information regarding NIPRO's products and services contained in this document is provided for informational purposes only and is not intended as a solicitation of customers, medical advice, or a recommendation regarding any medical treatment.

This document has been translated from the original Japanese version for reference purposes only. In the event of any discrepancy between the translated version and the original Japanese version, the original Japanese version shall prevail.

Table of Contents

Changes to Reporting Segments (Reintroduced)

To provide a clearer picture of our business operations, we have revised our segment effective from FY2026. *1

Previous Segment Classification

Segment	Products
Medical-Related Segment *2	Dialysis-Related Products
	Hospital-Related Products
	Vascular-Related Products
	Own-Brand Pharmaceuticals
	Regenerative Medicine Products
Pharmaceutical-Related Segment	CDMO
PharmaPackaging Segment	PharmaPackaging Products
Corporate & Adjustments	Headquarters Expenses

New Segment Classification（Effective FY2026）

Segment	Products
Medical-Related Segment *2	Dialysis-Related Products
	Hospital-Related Products
	Vascular-Related Products
Pharmaceutical-Related Segment	Own-Brand Pharmaceuticals
	CDMO
PharmaPackaging Segment	PharmaPackaging Products
Corporate & Adjustments	Headquarters Expenses
	Regenerative Medicine Products

*1 This reclassification is based on a review of management and reporting categories and has no impact on consolidated financial results.
*2 Medical Pharmaceuticals continues to be reported under the Medical-Related Business, with no change in classification.

Q1 FY2026 Results

(¥ 100 million)	Q1 FY2025	Q1 FY2026	Change (Change %)	Change Excl. FX Impact (Change %)	FY2026 Forecast (Profit ratio)	Quarterly Results FY2025 Q1	Quarterly Results FY2025 Q2	Quarterly Results FY2025 Q3	Quarterly Results FY2025 Q4	Quarterly Results FY2026 Q1
Net sales	1,592.2	**1,675.4**	+83.2	+22.0	**7,000.0**	**1,592.2**	**1,581.6**	**1,699.2**	**1,732.3**	**1,675.4**
			+5.2%	+1.4%						
Cost of sales *1	1,087.1	**1,135.7**	+48.5	+22.2	**4,650.0**	**1,087.1**	**1,078.4**	**1,183.9**	**1,159.0**	**1,135.7**
			+4.5%	+2.0%						
Gross profit *2	505.0	**539.7**	+34.6	-0.1	**2,350.0**	**505.0**	**503.1**	**515.3**	**573.2**	**539.7**
	31.7%	32.2%	+6.9%	-0.0%	33.6%	31.7%	31.8%	30.3%	33.1%	32.2%
SG&A expenses	432.9	**462.6**	+29.7	+12.9	**1,950.0**	**432.9**	**421.8**	**401.2**	**464.5**	**462.6**
	27.2%	27.6%	+6.9%	+3.0%	27.9%	27.2%	26.7%	23.6%	26.8%	27.6%
Operating profit	72.1	**77.1**	+4.9	-13.1	**400.0**	**72.1**	**81.2**	**114.0**	**108.7**	**77.1**
	4.5%	4.6%	+6.9%	-18.2%	5.7%	4.5%	5.1%	6.7%	6.3%	4.6%
Ordinary profit *3	35.1	**66.0**	+30.8	-	**274.0**	**35.1**	**47.1**	**93.7**	**21.1**	**66.0**
	2.2%	3.9%	+87.8%	-	3.9%	2.2%	3.0%	5.5%	1.2%	3.9%
Profit attributable to owners of parent	32.7	**38.3**	+5.6	-	**150.0**	**32.7**	**26.3**	**107.7**	**-31.7**	**38.3**
	2.1%	2.3%	+17.4%	-	2.1%	2.1%	1.7%	6.3%	-1.8%	2.3%

*1 A portion of manufacturing costs related to regenerative medicine has been reclassified to research and development expenses, with prior year figures adjusted accordingly.

*2 Effect of unrealized gains on gross profit
1Q FY2025 -¥920 million
1Q FY2026 -¥230 million

*3 Foreign exchange gains
1Q FY2025 -¥1,300 million
1Q FY2026 -¥1,730 million

Net Sales

Medical-Related Segment : Overseas – Sales growth in hospital-related, dialysis-related, and vascular-related products.
Domestic – Sales growth in hospital-related and dialysis-related products.
Pharmaceutical-Related Segment : Sales growth in injectable drugs and infusion products in own-brand pharmaceuticals.

Operating Profit

Operating profit increased, as lower SG&A expenses offset higher personnel costs, while sales growth, improved profitability, and favorable foreign exchange effects contributed to profit growth.

Q1 FY2026 Operating Profit Bridge



Approach to Achieving Full-Year Profit Forecasts

Item		Details	Timing	Impact
Medical-Related	Americas	Profit Contribution from new dialyzer "ELISIO™-HX"	FY2026 H2	Included in forecast
	Japan	Dialyzer Sales Growth and Profitability Improvement		
Pharmaceutical-Related	Own-Brand Pharmaceuticals	FORXIGA® AG Launch		
		Launch of Two GE Products		
	CDMO	Price increases		
Cost Structure Improvement		Reduction of Loss-Making Products SG&A Expenses Control Production Efficiency Improvements	FY2026 Full Year	
Medical-Related	Japan	Price increases	FY2026 H2	Not Included in forecast

Segment Sales & Segment Profit

Profit decreased in the Medical-Related segment due to the consolidation impact of Gentuity. Meanwhile, profit in the Pharmaceutical-Related segment declined due to lower cost variance gains.

(¥ 100 million)	Segment Sales					Segment Profit			
	Q1 FY2025	Q1 FY2026	Change %	Change Excl. FX Impact (Change %)	FY2026 Forecast (Achievement %)	Q1 FY2025	Q1 FY2026	Change %	FY2026 Forecast (Profit ratio)
Consolidated Total	1,592.2	**1,675.4**	+5.2%	+1.4%	7,000.0 23.9%	72.1	**77.1**	+6.9%	400.0 5.7%
Medical-Related segment	1,054.3	**1,119.3**	+6.2%	+1.4%	4,691.0 23.9%	103.1	**98.5**	- 4.5%	445.0 9.5%
Pharmaceutical-Related segment	399.6	**406.8**	+1.8%	+1.6%	1,697.0 24.0%	40.1	**37.3**	- 6.9%	146.0 8.6%
PharmaPackaging segment	134.1	**144.1**	+7.5%	+0.1%	582.0 24.8%	1.4	**1.4**	- 4.5%	16.0 2.7%
Corporate & Adjustments	3.9	**5.0**	+26.9%	-	30.0 16.9%	- 72.6	**- 60.1**	-	- 207.0 -





Medical-Related Segment

(¥100million)	Q1 FY2025	Q1 FY2026	Change%	Growth Rate Excluding FX Impact	Key Drivers of Changes
Segment Sales	1,054.4	1,119.3	+6.2%	+1.4%	● In Japan, business continued to recover, supported by a rebound in dialyzer sales. ● Overseas sales increased due to tender activities for hospital-related products and dialysate, as well as expanded sales activities for vascular-related products. Favorable foreign exchange rates also contributed to the increase.
Japan	343.8	372.9	+8.5%	+8.4%	● Dialyzers: Sales increased due to the recovery in fineflux® sales and stronger sales of maxiflux® driven by expanded sales activities. ● Needles: Sales increased due to stockpiling demand related to Middle East tensions. ● Injectable drugs and Infusion products: Sales increased due to price increases.
Americas	298.4	295.4	-1.0%	-4.1%	● Dialyzers: Sales increased in Latin America due to tender activities, meanwhile sales in North America decreased in anticipation of the ELISIO™-HX transition. ● Other dialysis-related products : sales from dialysis centers increased in Latin America due to higher demands, while dialysate sales increased in Mexico due to tender activities.
Europe	218.3	237.0	+8.6%	-5.4%	● Favorable foreign exchange rates. ● Dialyzers : Sales decreased due to competition from low-priced competitors. ● Needles〈Blood Collection Needles〉: Sales decreased due to lower demand resulting from inventory adjustment at OEM customers.
Asia	103.5	115.2	+11.4%	+8.0%	● Needles〈Blood Collection Needles〉: Sales increased due to tender activities and expanded production capacity. ● Vascular-related Products: Sales increased due to expanded sales activities.
China	90.2	98.6	+9.2%	+0.1%	● Dialyzers: Sales increased due to ongoing Volume-Based Procurement (VBP) and price increases. ● Other dialysis-related products: sales from dialysis centers increased due to growth in the dialysis patient population. ● Vascular-related Products: Sales decreased due to purchase postponement ahead of VBP implementation. ● Dialysis Machines: Sales decreased due to policies favoring domestically manufactured products.
Segment Profit	103.1	98.5	-4.5%	-	● Profit decreased YoY, as higher personnel expenses and increased R&D expenses associated with the consolidation of Gentuity LLC more than offset gross profit improvement driven by sales growth and lower raw material costs.

*Middle East sales, which were previously reported within Asia, have been included in Europe since FY2026. Accordingly, Q1 FY2025 figures have been revised to reflect this change.
*OEM sales were previously disclosed separately. From FY2026, they are included in the Americas and Europe regions.

Pharmaceutical-Related Segment

(¥100million)	Q1 FY2025	Q1 FY2026	Change%	Growth Rate Excluding FX Impact	Key Drivers of Changes
Segment Sales	**399.6**	**406.8**	**+1.8%**	**+1.6%**	● Sales of own-brand Pharmaceuticals increased, as growth in biosimilars, oncology products, antimicrobial agents, and injectable drugs and infusion products more than offset the decline in oral drugs caused by NHI(National Health Insurance) drug price reductions. ● CDMO sales declined due to lower orders for brand-name/long-listed products and the impact of products scheduled for discontinuation.
Own-Brand Pharmaceuticals*	**228.8**	**245.1**	**+7.1%**	**+6.8%**	● Injectable drugs and infusion products : driven by strong sales of biosimilars, oncology products, and antimicrobial agents. ● Topical drugs : Sales recovered, driven by improved sales of Inhalation Powder, which had been subject to shipment restrictions in the previous fiscal year. ● Oral drugs: Continued negative impact from NHI drug price reductions.
CDMO	**170.8**	**161.6**	**-5.4%**	**-**	● GE products : Declined due to injectable order timing shifts, partially offset by strong oncology sales and higher oral formulation orders. ● Brand-name/long-listed products : Declined due to lower injectable orders and order timing shifts. ※Shipment timing fluctuations are temporary and expected to have a limited full-year impact.
Generic drugs	80.5	81.4	+1.1%	-	● Oral drugs : Orders increased, driven by higher demand for contract-manufactured products. ● Injectable drugs : Declined, despite strong oncology product sales, due to order timing shifts for certain contract-manufactured products.
Brand-name/ Long-listed drugs	83.8	68.8	-17.9%	-	● Injectable drugs : Declined significantly due to lower orders and shipment timing differences. ● Oral drugs : Declined slightly due to lower orders.
Other drugs	6.4	11.3	+77.0%	-	● Increased sales from pre-commercial trial manufacturing.
Segment Profits	**40.1**	**37.3**	**-6.9%**	**-**	● Profit declined YoY due to a lower cost variance gains resulting from the revision of standard costs at the beginning of the fiscal year, despite increased sales volume and improved capacity utilization from higher production.

* JMI Pharma is included in own-brand pharmaceuticals.

PharmaPackaging Segment

(￥100million)	Q1 FY2025	Q1 FY2026	Change%	Growth Rate Excluding FX Impact	Key Drivers of Changes
Segment Sales	134.1	144.1	+7.5%	+0.1%	● Sales increased, driven by higher sales of injectable drugs and infusion products in Japan and demand recovery for glass tubing for biopharmaceuticals and glass vials in the Americas. ● Sales increased despite lower sales of glass syringes and glass vials in Europe, supported by higher sales of glass ampoules and cartridges and favorable foreign exchange effects.
Japan	38.7	41.6	+7.6%	+7.5%	● Other products (injectable drugs, infusion products, kit products, dental anesthetics) : Higher shipments driven by continued supply shortages among competitors. ● Rubber stoppers(Other) : Higher sales following price increases.
Europe	61.6	62.5	+1.5%	-12.0%	● Favorable foreign exchange effects. ● Glass ampoules: Sales increased due to expanded sales, together with higher sales of cartridges and other products. ● Glass vials : Lower sales ● Glass syringes : Lower sales due to price competition from competitors.
America	25.6	30.5	+19.3%	+15.3%	● Glass vials : Sales growth was supported by higher sales volumes resulting from market recovery and customer transfers from a European subsidiary. ● Glass tubing : Higher demand for high value-added products for biopharmaceuticals.
Asia*1	8.1	9.3	+15.1%	+9.7%	● Glass tubing & Vial glass : Lower sales ● Glass tubing & Glass Ampoules & Vial glass in China : Higher sales
Segment Profit	1.4	1.4	-	-	● Labor cost reductions were offset by rising raw material prices and other factors, resulting in segment profit remaining at the prior-year level.

*1 While China and India were previously disclosed separately, they have been consolidated and reported as Asia since FY2026.

Capex

Expansion of Production Capacity and Reinforcement of Supply Capabilities, Primarily for Medical-Related Products.

(unit：￥100million)	Q1 FY2025	Q1 FY2026	Change
Capex	112.1	139.2	+27.1
Medical-Related	65.9	89.6	+23.6
Pharmaceutical-Related	25.5	27.3	+1.7
PharmaPackaging	13.2	17.7	+4.5
Corporate & Adjustments	7.3	4.5	- 2.8

*Capital expenditures include investments in tangible fixed assets only.

Medical-Related Segment

〈Key Capital Investments in FY2026 1Q〉

- ✓ Dialyzer capacity expansion at the Vietnam Plant.
- ✓ Construction of the new U.S. Plant.
- ✓ Land acquisition for relocation of the dialysis solution plant in Spain.

Pharmaceutical-Related Segment

〈Key Capital Investments in FY2026 1Q〉

- ✓ Vial Building at the Omi Plant.

PharmaPackaging Segment

〈Key Capital Investments in FY2026 1Q〉

- ✓ High-value-added syringe production line for the German plant. (already ordered)

Depreciation

Depreciation expenses decreased by ¥0.4 billion YoY, partly due to the adoption of the straight-line depreciation method for domestic group companies beginning in FY2026.

(unit： ￥100million)	Q1 FY2025	Q1 FY2026	Change
Depreciation	149.4	145.3	- 4.0
Medical-Related	82.0	80.3	- 1.7
Pharmaceutical-Related	36.7	35.6	- 1.1
PharmaPackaging	17.0	16.8	- 0.2
Corporate & Adjustments	13.5	12.6	- 0.9

FY2026 Forecast – Consolidated (Reposted)

(unit : ¥100million)	FY2025 Actual	FY2026 Forecast *	Change % *¥ base
Net sales	6,605.3	**7,000.0**	+394.7
			+6.0%
Cost of sales	4,522.5	**4,650.0**	+127.5
			+2.8%
Gross profit	2,082.8	**2,350.0**	+267.2
	31.5%	33.6%	+12.8%
SG&A expenses	1,706.5	**1,950.0**	+243.5
	25.8%	27.9%	+14.3%
Operating profit	376.2	**400.0**	+23.8
	5.7%	5.7%	+6.3%
Ordinary profit	197.2	**274.0**	+76.8
	3.0%	3.9%	38.9%
Profit attributable to owners of parent	135.0	**150.0**	+15.0
	2.0%	2.1%	+11.1%

<Average rate>

	FY2025 Average Exchange rate	FY2026 Forecast rate	Change %
USD	149.7	**143.0**	-4.5%
EUR	169.5	**169.0**	-0.3%
CNY	20.8	**20.0**	-3.8%

*The FY2026 forecast has been calculated based on information currently available to the Company. As it is difficult to reasonably estimate the potential impact of the situation in the Middle East, such impact has not been reflected in the FY2026 forecast.

FY2026 Forecast – Segment（After Segment Reclassification）

■ Medical-Related Segment Sales / Profit

(unit： ¥100million)	FY2023 Actual	FY2024 Actual	FY2025 Actual	FY2026 Forecast
Segment Sales	3,663.8	4,180.5	4,362.7	**4,691.0**
Japan	1,346.9	1,405.9	1,463.8	**1,515.0**
Americas	914.1	1,150.5	1,212.8	**1,227.0**
Europe	705.9	836.0	907.9	**969.0**
Asia	381.1	448.1	415.2	**583.0**
China	315.8	340.0	363.0	**397.0**
Segment Profit	316.8	365.9	444.1	**445.0**

FY2026 Forecast – Segment（After Segment Reclassification）

■ Pharmaceutical-Related Segment Sales / Profit

(unit：￥100million)		FY2023 Actual	FY2024 Actual	FY2025 Actual	FY2026 Forecast
Segment Sales		1,606.9	1,653.6	1,673.8	**1,697.0**
Own-Brand Pharmaceuticals		926.8	935.6	947.5	**990.0**
CDMO	Generic drugs	381.4	335.5	320.2	**310.0**
	Brand-name drugs Long-listed drugs	251.3	334.7	356.3	**359.0**
	Other drugs	47.5	47.7	49.8	**38.0**
Segment Profit		88.8	149.3	153.7	**146.0**

FY2026 Forecast – Segment（After Segment Reclassification）

■ PharmaPackaging Segment Sales / Profit

(unit：￥100million)	FY2023 Actual	FY2024 Actual	FY2025 Actual	FY2026 Forecast
Segment Sales	580.5	592.8	547.1	**582.0**
Japan	131.4	143.2	152.8	**149.0**
Europe	251.8	280.9	258.8	**281.0**
Americas	141.3	129.7	102.0	**119.0**
Asia	56.0	39.0	33.4	**33.0**
Segment Profit	21.1	0.4	-15.0	**16.0**

FY2026 Forecast – Segment（After Segment Reclassification）

■ Capex / Depreciation

(unit : ¥100million)	Capex *1				Depreciation			
	FY2023 Actual	FY2024 Actual	FY2025 Actual	FY2026 Forecast	FY2023 Actual	FY2024 Actual	FY2025 Actual	FY2026 Forecast
Consolidated Total	953.4	740.5	640.7	**490.2**	560.3	625.0	616.7	**581.5**
Medical-Related	463.5	386.0	335.2	**244.0**	271.4	325.3	341.7	**318.0**
Pharmaceutical-Related *2	306.4	170.6	221.2	**151.1**	159.4	161.0	154.6	**141.0**
PharmaPackaging	166.3	128.7	68.1	**57.2**	69.1	81.0	64.2	**69.5**
Corporate & Adjustments	17.0	55.0	16.0	**37.9**	60.2	57.6	56.1	**53.0**

*1 Capex includes only investments in tangible fixed assets.
*2 Excluding subsidies related to NIPRO Pharma's Omi Plant.

■ R&D Expenses

(unit : ¥100million)	FY2023 Actual	FY2024 Actual	FY2025 Actual	FY2026 Forecast
Consolidated Total	257.3	278.6	268.1	**284.0**
Medical-Related	126.4	151.4	150.9	**157.0**
Pharmaceutical-Related	84.3	80.7	74.7	**82.0**
PharmaPackaging	5.2	5.5	4.4	**10.0**
Corporate & Adjustments	41.2	40.8	37.9	**35.0**

Appendix

TOPICS

Strategic Investments for long-term Growth

April 2026: Completion of the General Injectable Drug Facility (Vial Building) at Omi Plant of NIPRO Pharma Corporation

- Trial production is scheduled to begin in preparation for commercial production starting in November 2026. The facility is capable of “dual-use” manufacturing, producing standard injectable drugs under normal conditions and vaccines during emergencies, such as infectious disease outbreaks.
- The project was the sole formulation manufacturing project selected in the first round of METI's Program for the Development of Biopharmaceutical Manufacturing Facilities to Strengthen Vaccine Production Capacity. Subsidies for the facility and manufacturing equipment are expected to be received within FY2026, with minimal P/L impact due to compression accounting.
- Through the strategic collaboration with Chugai Pharmaceutical Co., Ltd., we are strengthening our manufacturing capabilities to meet global GMP standards and support product supply to global markets.

June 2026: Supplemental NHI Listing of the Company's Fourth Authorized Generic (AG) Product

- NIPRO‘s authorized generic (AG), ｢Dapagliflozin Tablets 5 mg/10 mg “NIPRO,”｣ was listed on the NHI drug price list as an authorized generic version of the brand-name product ｢FORXIGA® Tablets 5 mg/10 mg｣.
- Following the revision of the AG system, this product will be the final authorized generic product to receive an additional NHI price listing under the current system.
- Commercial launch is scheduled for around September 2026. Expanding the lineup of type 2 diabetes treatments will further enhance our diabetes-related product portfolio and strengthen both our business foundation and earnings base.

(NIPRO's product is not indicated for type 1 diabetes, chronic heart failure, or chronic kidney disease.)

Net Sales by Segment and Region *Based on destination

Segment / Region (unit：￥100million)		Medical -Related	Pharmaceutical -Related	Pharma Packaging	Other	Total
Japan	**Q1 FY2026**	**373.7**	**381.3**	**41.8**	**4.9**	**801.8**
	Q1 FY2025	345.9	378.5	38.8	3.7	767.1
Overseas Total	**Q1 FY2026**	**745.5**	**25.5**	**102.3**	**0.1**	**873.6**
	Q1 FY2025	708.4	21.0	95.3	0.2	825.0
Americas	**Q1 FY2026**	**299.5**	**-**	**26.6**	**0.0**	**326.2**
	Q1 FY2025	305.9	-	25.3	0.0	331.3
Europe	**Q1 FY2026**	**192.9**	**0.8**	**64.8**	**0.0**	**258.6**
	Q1 FY2025	163.0	1.7	61.5	-	226.3
China	**Q1 FY2026**	**100.0**	**0.1**	**6.9**	**0.0**	**107.1**
	Q1 FY2025	91.0	0.1	4.7	0.0	95.9
Asia	**Q1 FY2026**	**153.0**	**24.5**	**4.0**	**0.0**	**181.6**
	Q1 FY2025	148.2	19.2	3.7	0.2	171.4
Consolidated Total	**Q1 FY2026**	**1,119.3**	**406.8**	**144.1**	**5.0**	**1,675.4**
	Q1 FY2025	1,054.3	399.6	134.1	3.9	1,592.2

Net Sales by Product Category *Based on destination

	(unit : ¥ 100 million)	Overall				Overseas				Japan			
		Q1 FY2025	Q1 FY2026	Change	Change %	Q1 FY2025	Q1 FY2026	Change	Change %	Q1 FY2025	Q1 FY2026	Change	Change %
Medical-Related Segment	Dialyzers	282.5	288.6	+6.0	+2.1%	229.3	225.2	-4.1	-1.8%	53.1	63.3	+10.1	+19.1%
	Dialysis machine	72.0	72.6	+0.5	+0.8%	60.1	60.4	+0.2	+0.5%	11.9	12.2	+0.2	+2.4%
	Other dialysis-related products	217.5	244.2	+26.6	+12.3%	178.0	203.5	+25.5	+14.3%	39.4	40.6	+1.1	+3.0%
	Dialysis-Related Products Total	**572.1**	**605.5**	**+33.3**	**+5.8%**	**467.5**	**489.2**	**+21.7**	**+4.6%**	**104.6**	**116.2**	**+11.6**	**+11.1%**
	Needles	152.5	169.0	+16.5	+10.8%	107.9	115.6	+7.7	+7.1%	44.5	53.3	+8.8	+19.8%
	Infusion-related products	54.7	58.1	+3.3	+6.2%	24.9	25.7	+0.8	+3.4%	29.8	32.3	+2.5	+8.5%
	Diabetes-related products	32.2	30.4	-1.7	-5.5%	28.4	27.4	-0.9	-3.3%	3.8	2.9	-0.8	-21.8%
	Other hospital-related products	155.2	161.5	+6.3	+4.1%	55.2	55.7	+0.4	+0.8%	99.9	105.8	+5.9	+5.9%
	Hospital-Related Products Total	**394.8**	**419.2**	**+24.4**	**+6.2%**	**216.6**	**224.7**	**+8.0**	**+3.7%**	**178.1**	**194.5**	**+16.4**	**+9.2%**
	Vascular products	**87.3**	**94.5**	**+7.2**	**+8.2%**	**24.1**	**31.5**	**+7.3**	**+30.4%**	**63.1**	**63.0**	**-0.1**	**-0.2%**
	Medical Segment Total	**1,054.3**	**1,119.3**	**+64.9**	**+6.2%**	**708.4**	**745.5**	**+37.1**	**+5.2%**	**345.9**	**373.8**	**+27.8**	**+8.1%**
Pharmaceutical-Related Segment	Oral drugs	135.5	130.6	-4.9	-3.7%	18.5	22.5	+4.0	+21.8%	117.0	108.0	-9.0	-7.7%
	Injectable drugs and infusion products	70.9	90.2	+19.2	+27.2%	0.1	0.2	+0.0	+31.8%	70.7	89.9	+19.2	+27.2%
	Others	20.0	22.1	+2.0	+10.2%	0.1	0.0	+0.0	-42.7%	19.8	22.0	+2.1	+10.7%
	Own-Brand Pharmaceuticals Total	**226.5**	**242.9**	**+16.3**	**+7.2%**	**18.8**	**22.9**	**+4.0**	**+21.4%**	**207.6**	**220.0**	**+12.3**	**+5.9%**
	Oral drugs	63.2	69.9	+6.7	+10.6%	0.2	0.1	+0.0	-41.6%	63.0	69.8	+6.8	+10.8%
	Injectable drugs and infusion products	97.6	77.0	-20.6	-21.1%	1.4	0.9	-0.4	-34.1%	96.2	76.0	-20.1	-20.9%
	Others	12.2	16.9	+4.6	+38.2%	0.5	1.5	+0.9	+169.8%	11.6	15.3	+3.7	+31.8%
	CDMO Pharmaceuticals Total	**173.1**	**163.8**	**-9.2**	**-5.3%**	**2.1**	**2.5**	**+0.3**	**+17.9%**	**170.9**	**161.3**	**-9.6**	**-5.6%**
	Pharmaceuticals Segment Total	**399.6**	**406.8**	**+7.1**	**+1.8%**	**21.0**	**25.5**	**+4.4**	**+21.0%**	**378.5**	**381.3**	**+2.7**	**+0.7%**
PharmaPackaging Segment	Glass tubig-related products	33.1	33.7	+0.6	+1.9%	26.2	26.5	+0.3	+1.3%	6.8	7.1	+0.2	+4.2%
	Glass ampoules	18.4	22.6	+4.1	+22.4%	18.4	22.5	+4.1	+22.5%	0.0	0.0	+0.0	-15.2%
	Glass vials	31.1	32.2	+1.0	+3.5%	24.6	26.1	+1.5	+6.2%	6.5	6.0	-0.4	-7.1%
	Glass syringes	19.5	14.7	-4.7	-24.4%	19.4	14.7	-4.7	-24.5%	0.0	0.0	+0.0	+22.0%
	Other products	31.8	40.8	+8.9	+28.1%	6.5	12.3	+5.8	+89.1%	25.3	28.5	+3.1	+12.4%
	PharmaPackaging Segment Total	**134.1**	**144.1**	**+10.0**	**+7.5%**	**95.3**	**102.3**	**+7.0**	**+7.4%**	**38.8**	**41.8**	**+2.9**	**+7.7%**
Corporate & Adjustments	**Sales of production machinery and real estate leasing**	**2.3**	**2.4**	**+0.0**	**+3.6%**	**0.0**	**0.0**	**+0.0**	**+121.0%**	**2.3**	**2.4**	**+0.0**	**+3.1%**
	Regenerative medicine products	**1.2**	**2.2**	**+0.9**	**+74.8%**	**-**	**-**	**-**	**-**	**1.2**	**2.2**	**+0.9**	**+74.8%**
	Corporate & Adjustments Total	**3.9**	**5.0**	**+1.0**	**+26.9%**	**0.2**	**0.1**	**+0.0**	**-34.7%**	**3.7**	**4.9**	**+1.1**	**+31.0%**
	Consolidated Total	**1,592.2**	**1,675.4**	**+83.2**	**+5.2%**	**825.0**	**873.5**	**+48.4**	**+5.9%**	**767.1**	**801.8**	**+34.7**	**+4.5%**

Exchange rate, sensitivity / Product Category

<Average rate>

	FY2025				FY2026				
	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Jan-Mar	Jan-Jun	Jan-Sep	Jan-Dec	Forecast
¥/USD	151.21	147.48	147.78	149.78	156.45	-	-	-	143.00
¥/EUR	159.35	162.24	165.57	169.53	183.53	-	-	-	169.00
¥/CNY	20.75	20.34	20.48	20.87	22.64	-	-	-	20.00

<Closing rate>

	FY2025 As of Jun.31	FY2026 As of Jun.31
¥/USD	144.81	162.39
¥/EUR	169.66	185.35
¥/CNY	20.19	23.87

<FX Sensitivity>
*¥1 Yen Depreciation

¥100M	Net Sales	Operating Profit
¥/USD	10.0	-0.2
¥/EUR	6.4	1.9
¥/CNY	18.6	7.6

<Product Category>

Category		Product Group	Key Products
Medical-Related Segment	Dialysis-Related Products	Dialyzers	Dialyzers (artificial kidneys), HDF filters
		Dialysis machine	Dialysis systems, maintenance, dialysis machine parts
		Other dialysis-related products	Blood circuits, AVF needles (Winged IV Catheters), Powdered Dialysate, Dialysis fluids, etc.
	Hospital-Related Products	Needles	PSV needles(Winged IV Catheters), Safetouch needles, etc.
		Infusion-related products	Infusion sets, IV cannulas, etc.
		Diabetes-related products	Insulin needles, Blood glucose meters (for overseas markets), lancets
		Other hospital-related products	Gloves、Mechanical circulatory support, Cardiopulmonary bypass products、Neo tube, prefilled syringe products (saline, heparin, etc.), and others.
	Vascular-Related Products	Vascular products	Catheter sets for cardiovascular treatments, Thrombus aspiration catheters, etc.
Pharmaceutical-Related Segment	Own-Brand Pharmaceuticals /CDMO	Oral drugs	Oral drugs
		Injectable drugs and infusion products	Syringe kits, Vial formulations, Dual chamber bags (PLW) , etc.
		Other drugs	Topical drugs, patches、Diagnostic Reagents, etc.
PharmaPackaging Segment	PharmaPackaging Products	Glass tubing-related products	Medical-use glass tubing, Non-medical use glass tubing
		Glass ampoules	Ampoules (Single tip, Double tip)
		Glass vials	Vials (Blowback, Screw, etc.)
		Glass syringes	Syringes（Luer lock, Luer slip, Sterilized, etc.)
		Other PharmaPackaging products	Rubber stoppers, Plastics, Cartridge glass and others, etc.
Corporate ＆ Adjustments		Regenerative Medicine	
		Machinery Sales and Real Estate Leasing	

NIPRO

Live Longer. Live Better.